Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a new clinical entity that was reclassified from enteropathy-associated T-cell lymphoma in the 2016 WHO classification. An 83-year-old man with fever and diarrhea was referred to our hospital because of free air in the abdominal cavity and wall thickening of the large intestine on CT. Colonofiberscopic examination revealed mucosal edema and multiple ulcers at the sigmoid colon, splenic flexure, and transverse colon. Histopathological examination of the mucosal biopsy specimen demonstrated dense infiltration of small lymphocytes with nuclear atypia, some of which exhibited intraepithelial invasion. Immunohistologically, these lymphocytes were positive for CD3, CD56, and perforin. Regarding CD3 expression, the antigen was found to only be expressed in the cytoplasm and not on the surface membrane on flow cytometric analysis. PCR examination of the T-cell receptor (TCR) gene revealed monoclonal gene rearrangements of TCR-γ and TCR-β. Based on these findings, a diagnosis of colonal MEITL with cyCD3 expression at Lugano clinical stage 1 was made. After conservative management of the peritonitis, we treated the patient with CHOP and DeVIC regimens, but he developed progressive disease and died. The cyCD3 expression in MEITL may be novel, suggesting a thymocyte origin of the tumor cells.
Study Design: This experimental study was performed using human ligamentum flavum–derived cells (HFCs).Purpose: To investigate the intracellular signaling mechanism of interleukin-6 (IL-6) secretion in transforming growth factor-β (TGF- β)-stimulated HFCs.Overview of Literature: Lumbar spinal stenosis (LSS) is a prevalent disease among the elderly, characterized by debilitating pain in the lower extremities. Although the number of patients with LSS has increased in recent years, the underlying pathomechanism remains unclear. Clinical examinations typically rely on magnetic resonance imaging to diagnose patients, revealing ligamentum flavum hypertrophy. Some studies have suggested an association between ligamentum flavum hypertrophy and inflammation/fibrosis, and expression of TGF-β and IL-6 has been observed in surgically obtained ligamentum flavum samples. However, direct evidence linking TGF-β and IL-6 expression in HFCs is lacking.Methods: HFCs were obtained from patients with LSS who had undergone decompression surgery. The cells were stimulated with TGF-β and pretreated with either the p38 mitogen-activated protein (MAP) kinase inhibitor SB203580 or the p44/42 MAP kinase inhibitor FR180204. IL-6 secretion in the cell culture medium and IL-6 messenger RNA (mRNA) expression levels were analyzed using an enzyme-linked immunoassay and real-time polymerase chain reaction, respectively.Results: TGF-β administration resulted in a dose- and time-dependent stimulation of IL-6 release. Treatment with SB203580 and FR180204 markedly suppressed TGF-β–induced IL-6 secretion from HFCs. Moreover, these inhibitors suppressed IL-6 mRNA expression in response to TGF-β stimulation.Conclusions: Our findings indicate that TGF-β induces IL-6 protein secretion and gene expression in HFCs through the activation of p38 or p44/42 MAP kinases. These results suggest a potential association between IL-6–mediated inflammatory response and tissue hypertrophy in LSS, and we provide insights into molecular targets for therapeutic interventions targeting LSS-related inflammation through our analysis of the MAP kinase pathway using HFCs.
1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
【Background】Polyphenol compounds in foods contain antioxidants and are known to have effects of liver protection, hypoglycemic, and cholesterol-lowering. Colorectal cancer is one of the most types of cancers and the mortality rate is the second-highest in Japan. Since cancer stem cells are related to drug resistance and recurrence of colorectal cancer, a new remedy that targets cancer stem cells is needed. In the previous study, we established a novel culture method of the human colorectal air-liquid interface (ALI) organoids, which could recapitulate three-dimensional cancer microenvironment including patient-derived cancer stem cells. In this study, we investigated whether polyphenol antioxidants affect the survival rate of human colorectal ALI organoids and analyzed the inhibitory mechanisms.【Methods and results】Organoids were treated with polyphenol antioxidants at the dose of 3-100 μg/ml for 72 hours. The survival rate of organoids was measured by alamarblue assay. Polyphenol antioxidants suppressed survival rate of organoids in a concentration-dependent manner. The expression of marker genes for cancer stem cells, LGR5 and PROM1 were drastically decreased by polyphenol antioxidants. Expression of a G1/S transition-related gene, CCND1 was also decreased.【Conclusion】These results suggest that polyphenol antioxidants inhibit proliferation of human colorectal cancer stem cells via suppression of LGR5, PROM1, and CCND1, which might lead to the development of dietary supplements targeting colorectal cancer stem cells.
1 January 2021 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
【Background】Since the malignancy of dog bladder cancer (BC) is higher than human BC, most BC bearing dogs die early. In our laboratory, we established the method of bladder cancer organoid culture using the cancer stem cells in their urine samples. On the one hand, the usage of traditional Chinese medicine has been increasing in veterinary medicine. In our laboratory, we treated dog BC organoids with 39 kinds of traditional Chinese medicines. Among them, we clarified anti-proliferative effects of Chaga mushroom and Panax notoginseng-containing traditional Chinese medical supplement, Shibe-ria on dog BC stem cells. 【Object】This study aimed to clarify anti-proliferative mechanisms and components of Shibe-ria on dog BC organoids.【Methods and Results】Dog BC organoids were treated with Shibe-ria (100 μg/ml) for 6-24 hours and the expression of cancer stem cell markers was evaluated using Real time PCR. The expression of CD44 and SOX2 mRNA was significantly reduced. On the one hand, Dog BC organoids were treated with Shibe-ria extracted by various solvents (50-100 μg/ml) for 72 hours, respectively. The cell viability of the organoids was assessed by Alamarblue assay. Shibe-ria extracted by 20 %, 50 %, 70 % methanol suppressed cell viability of dog BC organoids. 【Discussion】We for the first time demonstrated that Shibe-ria inhibited the proliferation of dog BC organoids by suppressing expression of CD44 and SOX2 mRNA. Components in Shibe-ria extracted by 20 %, 50 %, 70 % methanol were suggested to inhibit the proliferation of dog BC organoids.
1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
【Background】- Since dog bladder cancer is usually muscle-invasive and the malignant level is quite high, the proper treatment has not been established in a veterinary clinic. In the previous study, we generated a dog bladder cancer organoids, which could reproduce the cancer microenvironment in vivo and could be applied to the anti-cancer drug sensitivity test for each patient. However, it has not been revealed whether molecular targeting drugs are effective in the inhibition of the survival of the organoids.【Object】-The purpose of this study is to identify the effective molecular targeting drugs against dog bladder cancer by using dog bladder cancer organoids.【Method】-Dog bladder cancer organoids were treated with 14 molecular targeting drugs for 72hours. The survival rate of organoids was evaluated by an alamarblue cell viability reagent. The effects of drugs on the activation and expression of intracellular signal molecules were investigated by performing western blotting.【Result】-Among 14 drugs, treatment of gefitinib, erlotinib, trametinib, and afatinib inhibited the cell viability of organoids in a dose-dependent manner. Furthermore, EGFR, and ERK, and CD44 expression were suppressed by erlotinib treatment.【Conclusion】-These results suggest that EGFR inhibitors and a MEK inhibitor might suppress the growth of dog bladder cancer organoids through suppression of CD44 expression. This result is expected to be useful for the development of molecular targeting therapy for bladder cancer diseased dog.